You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Cyclerion reveals data for schizophrenia therapy

Cyclerion Therapeutics has announced positive top line data from its clinical study of CY6463 for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS).